SEC Form 4 · accession 0001181431-15-004695
Pacira BioSciences, Inc. · PCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John P Longenecker Ph.D.
Director
Period of report
Mar 12, 2015
Accepted (ET)
Mar 16, 2015 · 8:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001396814
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 12, 2015 | M | 3,000 | $29.90 | A | 3,000 | D | |
| Common StockF3 | Mar 12, 2015 | S | 3,000 | $95.28 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $29.90 | Mar 12, 2015 | M | 3,000 | D | — | Jun 11, 2023 | Common Stock | 3,000 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- F2The option shares vest in 12 equal successive monthly installments over the 12-month period following the date of grant, subject to the reporting person's continued service as a director.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.26 to $95.37, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.